Global GLP-1 Receptor Agonist Market Research Report: Forecast (20262032) Global GLP-1 Receptor Agonist Market - By Product Type (Semaglutide, Ozempic, Wegovy, Rybelsus, Others, Liraglutide, Victoza, Saxenda, Others, Exenatide, Dulaglutide, Other (tirzep
Wegovy contains a higher dose of semaglutide than Ozempic
Indication bias remains a limitation, as finerenone was more frequently prescribed to patients with lower eGFR and higher potassium levels, though we adjusted for complications and cardiorenal risk factors associated with diabetes as proxy of disease severity, which likely mitigated potential bias
Regulatory frameworks are still developing, but there is a growing interest from governments to promote health supplements, which could catalyze market growth in the coming years